ライフサイエンスコーパス: BED

1 BED and PG are thus dissociable as a function of dopamin

2 BED as a continuous variable significantly affected LC (

3 BED subjects showed widespread reductions in [(11)C]carf

4 BED testing demonstrated high reproducibility among all

5 BED-FRAME evaluates diagnostic yield and addresses 2 key

6 BED-FRAME is a useful fundamental supplement to the stan

7 BED-FRAME provides a tool for communicating the expected

8 The HIV-1 BED incidence assay was developed at the Centers for Dis

9 robands with (n = 150) and without (n = 150) BED, and their first-degree relatives (n = 888) in a com

10 dose distributions were used to generate 3D BED distributions.

11 Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [(11)C]carfentan

12 A BED greater than 80.5 Gy seems to be an ablative dose of

13 A BED-specific proficiency testing (PT) program was initia

14 rate was significantly higher (78%) after a BED greater than 80.5 Gy than after lower doses (45%, P

15 ore, which suggests a possible origin from a BED finger-like intermediate that was in turn ultimately

16 Results are exported in a BED format for rapid visualization in the UCSC genome br

17 incarceration, we tested their sera using a BED HIV-1 capture enzyme immunoassay to estimate HIV inc

18 he effects of group CBT and group IPT across BED-related symptoms among overweight individuals with B

19 exia nervosa and bulimia nervosa, and adding BED as a specified eating disorder.

20 Role impairments are similar for BN and BED.

21 tides encompassing the proximal, distal, and BED/AP-1-binding regions failed to demonstrate selective

22 ad WB (0.90); within 60 days, the LS-EIA and BED (both 0.85); and for persons within 90 days the BED

23 cing transcript structures from GFF/GFF3 and BED files.

24 ced by most RNA-seq mapping tools as well as BED files, which are widely used for gene models.

25 The microarray data and associated .BED and .WIG files can be accessed through Gene Expressi

26 inc fingers 1 to 3 are potential DNA-binding BED finger domains recently proposed to play a role in a

27 of sequence alignments in BAM format to both BED and GFF features.

28 ded data set of 1354 specimens classified by BED, the optimized MBC performed significantly better th

29 developed an immunoglobulin G (IgG)-capture BED-enzyme immunoassay (BED-CEIA) to identify recent hum

30 participated in a 5-day bed rest challenge (BED REST).

31 genomic features in Browser Extensible Data (BED) and General Feature Format (GFF) format.

32 a formats including Browser Extensible Data (BED), bedGraph and Browser Extensible Data Paired-End (B

33 tirely to BN and to a somewhat lesser degree BED predicting subsequent onset of these conditions.

34 Binge-eating disorder (BED) is characterized by recurring episodes of excessive

35 ifetime prevalence of binge eating disorder (BED) was 2%.

36 e (LDX) vs placebo in binge eating disorder (BED) was evaluated in two multicenter, double-blind, pla

37 seeking treatment for binge eating disorder (BED) were compared with 19 non-BED obese individuals (OB

38 and without (n = 30) binge eating disorder (BED) were compared with matched healthy volunteers and t

39 Binge-eating disorder (BED), a public health problem associated with psychopath

40 dard for treatment of binge eating disorder (BED), most individuals do not have access to this specia

41 se disorders (AUD) or binge-eating disorder (BED), suggest a disturbance in explore-exploit decision-

42 Binge-eating disorder (BED)-a syndrome that only recently has attracted scienti

43 ecialty treatment for binge eating disorder (BED).

44 for the treatment of binge eating disorder (BED).

45 cal gambling (PG) and binge eating disorder (BED).

46 n the epidemiology of binge eating disorder (BED).

47 Women with binge-eating disorder (BED; n = 38) and age- and weight-matched women without B

48 d disorders somewhat more strongly than does BED.

49 d calculating tumor biologic effective dose (BED) along the normal-organ MTBED limits, we obtained th

50 c effects using biologically effective dose (BED) and equivalent uniform dose (EUD) was developed in

51 stribution by a biologically effective dose (BED) volume histogram (BVH).

52 and calculated biologically effective dose (BED) with radionuclide-induced nephrotoxicity.

53 tions for a median biologic equivalent dose (BED) of 80.5 Gy (range, 43.75 to 180 Gy).

54 Users submit a bedpe (paired-end BED format) file containing the locations and strengths

55 ation sequencing experiments, such as FASTQ, BED and BAM format files.

56 Finally, BED distributions were used to estimate an EUD for each

57 discovered transcription factor, zinc finger BED domain-containing protein 6 (ZBED6), is expressed in

58 Zinc finger, BED-type containing 6 (ZBED6) is an important transcript

59 The transcription factor ZBED6 (zinc finger, BED-type containing 6) is a repressor of IGF2 whose acti

60 We use assays for BED, avidity, viral load, and CD4 cell count data from c

61 rweight patients meeting DSM-IV criteria for BED were randomly assigned to 20 weekly sessions of eith

62 tly (median; interquartile range) higher for BED (1.4%; .8-1.9%) than BN (.8%; .4-1.0%).

63 utcome, including mortality, are limited for BED.

64 Risk Evaluation of Diagnostics: A Framework (BED-FRAME) is a strategy for pragmatic evaluation of dia

65 files in TAB-delimited formats such as GFF, BED, PSL, SAM and SQL export, and quickly retrieves feat

66 ensive output for identified peaks with GFF, BED, bedGraph and .wig formats, annotated genes to which

67 For elite suppressors, 10/18 had BED-CEIA values <0.8 normalized optical density units (O

68 For patients receiving ART, 14/18 had BED-CEIA values that decreased over time, with a median

69 ulin G (IgG)-capture BED-enzyme immunoassay (BED-CEIA) to identify recent human immunodeficiency viru

70 ted with the BED capture enzyme immunoassay (BED-CEIA) which measures the proportion of IgG that is H

71 includes the BED capture enzyme immunoassay (BED-CEIA), an antibody avidity assay, HIV load, and CD4(

72 includes the BED capture enzyme immunoassay (BED-CEIA), the Bio-Rad Avidity assay, viral load, and CD

73 breakthrough were associated with changes in BED-CEIA values, reflecting changes in the proportion of

74 in regional activation were investigated in BED, OB, and LC groups during reward/loss prospect, anti

75 Further investigation of lisdexamfetamine in BED is ongoing.

76 er and [(18)F]fluorodopa Ki was 20% lower in BED compared with PG and controls (p<0.002).

77 effective doses (BEDs) for a maximal kidney BED (20 Gy2.5) for different peptide amounts and activit

78 e tool and a python library that manipulates BED files of possibly irregularly spaced P-values and (1

79 ng the additional constraint of a red marrow BED less than 1 Gy15, was individually quantified.

80 Cross-national BED data are presented here and compared with bulimia ne

81 ing disorder (BED) were compared with 19 non-BED obese individuals (OB) and 19 lean control subjects

82 , for the purposes of exposition, nonuniform BED distributions are represented by normal distribution

83 ndicates that OSU6162 might serve as a novel BED medication.

84 tle is known about the course and outcome of BED in the community.

85 Three patterns of BED-CEIA values were observed during viral breakthrough:

86 Follow-up studies of BED are scarce; remission rates in randomized controlled

87 fficacy for the core and related symptoms of BED.

88 baseline data for the successful transfer of BED-CEIA to other laboratories and the use of BED-CEIA f

89 ED-CEIA to other laboratories and the use of BED-CEIA for the detection of recent HIV seroconversion

90 Fewer than half of lifetime BN or BED cases receive treatment.

91 accepts input sequences in either FASTA- or BED-formatted data files.

92 ts long-term impact and time course on other BED-related symptoms remain largely unknown.

93 g files) or functional genomic regions (peak/BED files).

94 Compared with PG, BED patients show widespread losses of mu-opioid recepto

95 The 3-year OS rate for patients receiving BED greater than 80.5 Gy was 73% versus 38% for those re

96 vealed a second functional YY1 binding site (BED) that overlaps with an AP1 binding site.

97 compared with each other or to AUD subjects, BED had enhanced exploratory behaviors particularly in t

98 adult outpatients with full or subsyndromal BED were recruited from 7 university-based outpatient cl

99 tly higher for BN (6.5 years; 2.2-15.4) than BED (4.3 years; 1.0-11.7).

100 uent onset of BN somewhat more strongly than BED and that BN predicts subsequent comorbid disorders s

101 itive (LS) enzyme immunoassay (EIA), and the BED assay.

102 ve for detecting recent HIV infection as the BED-CEIA and has a very low rate of false-recent misclas

103 was evaluated using 3 serologic assays: the BED capture enzyme immunoassay (CEIA), the Bio-Plex (Lum

104 No differences were observed between the BED and LC groups in the ventral striatum.

105 nce of different laboratories conducting the BED assay while identifying areas for improvements.

106 In contrast, the BED group relative to the OB group demonstrated diminish

107 th 0.85); and for persons within 90 days the BED (0.86).

108 LS-EIA (</=0.2 cutoff), 88% and 72% for the BED (</=0.2 cutoff), and 43%-58% and 98% (</=3 bands) fo

109 For the BED CEIA and Luminex assay, linear mixed effects models

110 of unlabeled antibody (cold protein) in the BED analysis were explored.

111 The MAAs that were evaluated included the BED-CEIA, the Bio-Rad Avidity assay, viral load, and the

112 hm (MAA) for HIV incidence that includes the BED capture enzyme immunoassay (BED-CEIA), an antibody a

113 ly identified a robust MAA that includes the BED capture enzyme immunoassay (BED-CEIA), the Bio-Rad A

114 tinct locations on domain 1 of ICAM-3 on the BED face (Asn23 and Ser25) and on the C strand or CD loo

115 molecule over a hydrophobic interface on the BED sheet of domain 1, in agreement with dimerization of

116 Thus, the BED-specific PT program enabled us to track performance

117 to compare the performance of the MAA to the BED-CEIA and to determine the window period of the MAA.

118 STARHS methodology uses the BED HIV-1 capture enzyme immunoassay to determine recent

119 f 6864 diagnostic specimens tested using the BED assay, 2133 (31%) were classified as recent infectio

120 HIV infection as recently infected using the BED-CEIA, thereby influencing a falsely high value for c

121 Samples were tested with the BED capture enzyme immunoassay (BED-CEIA) which measures

122 uring 2006 in 22 states were tested with the BED HIV-1 capture enzyme immunoassay to classify infecti

123 nting or treating traits influenced by these BED-specific familial factors could reduce the public he

124 Furthermore, these BED-specific familial factors may independently increase

125 1, n=383; study 2, n=390) meeting DSM-IV-TR BED criteria were randomized (1:1) to placebo or LDX (50

126 Tumor BED optimization results were calculated and plotted as

127 eptide amount and activity for maximal tumor BED, considering the additional constraint of a red marr

128 that would deliver 95% of the maximum tumor BED, allowing for informed inclusion of clinical conside

129 ing the ability to submit fuzzy sets, upload BED files, improved application programming interface an

130 However, it remains unclear whether BED represents an etiologically distinct behavioral phen

131 at analyses included 259 and 255 adults with BED, respectively.

132 lternative compared with CBT for adults with BED.

133 d symptoms among overweight individuals with BED.

134 Patients with BED display an addiction-like symptomatology and the dop

135 line treatment option for most patients with BED, with IPT (or full cognitive behavior therapy) used

136 tions in binge eating in obese patients with BED.

137 or the treatment of overweight patients with BED.

138 Furthermore, relatives of probands with BED displayed a markedly higher prevalence of severe obe

139 Obese subjects with and without BED did not differ from healthy volunteers but when comp

140 sorders of natural (obesity with and without BED) and drug rewards (AUD).

141 y equal magnitude for women with and without BED.

142 s observed in obese subjects with or without BED.

143 rs but not in obese subjects with or without BED.

144 ex >/=40) than relatives of probands without BED even when controlling for proband body mass index (o

145 8) and age- and weight-matched women without BED (n = 32) monitored their dietary intake and concurre